Type of information: Licensing agreement
Compound: next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology
Company: Cellular Biomedicine Group (China) National Cancer Institute (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism: immunotherapy product/cell therapy/tumor infiltrating lymphocytes
- • On October 3, 2018, Cellular Biomedicine Group, a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced it has entered into a patent license agreement with the National Cancer Institute, an institute of the National Institutes of Health, within the Department of Health and Human Services. Pursuant to the license agreement, NCI granted CBMG a non-exclusive, sub-licensable worldwide license to develop, manufacture and commercialize next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancers.